Pyridoclax

Pyridoclax is a small molecule inhibitor of the anti-apoptotic protein Mcl-1, belonging to the oligopyridine chemical family. It was designed to target the hydrophobic binding pocket of Mcl-1, thereby preventing its interaction with pro-apoptotic BH3-only proteins like Bim and Bak. This inhibition leads to the induction of apoptosis in cancer cells. Pyridoclax has demonstrated efficacy in preclinical models of chemoresistant ovarian cancer, both as a monotherapy and in combination with Bcl-xL inhibitors such as ABT-263 (navitoclax). The compound was developed through a collaborative effort involving Normandie University, INSERM, and CNRS.

Other names

Pyridoclax hydrochloride